Internal and Emergency Medicine

, Volume 5, Issue 4, pp 299–306

Venous thromboembolism prophylaxis with unfractionated heparin in the hospitalized medical patient: the case for thrice daily over twice daily dosing

  • Charles E. Mahan
  • Mario Pini
  • Alex C. Spyropoulos
IM - Review


For venous thromboembolism (VTE) prevention in the hospitalized medical patient, no head-to-head trials have been performed of unfractionated heparin (UFH) 5,000 U subcutaneously thrice (i.e. q8 h or TID) daily versus twice daily (q12 h or BID). Several meta-analyses have been undertaken in attempts to determine whether one regimen may be more beneficial for safety and efficacy. Currently, not all international guidelines include a recommended frequency for UFH. Delineation of this frequency may be helpful to the practicing clinician. Primary studies (with a modified Jadad score of ≥6 to demonstrate a stronger study design) that compared low molecular weight heparin (LMWH) and UFH, and UFH and placebo were evaluated. Meta-analyses evaluating safety and efficacy of LMWH versus UFH, or TID UFH versus BID UFH were also evaluated. Although BID UFH shows some efficacy in one primary study, it is no more beneficial than no prophylaxis in another study. LMWH appears to be more efficacious than BID UFH, but comparable in safety and efficacy to TID UFH. Meta-analytic data demonstrates that BID UFH may have some reduction in deep vein thrombosis. Meta-analytic data also suggests that TID UFH is more efficacious than BID UFH at the cost of more major bleeding. The medical patient with risk factors for the development of VTE appears to be at moderate to high risk. International guidelines for VTE prevention should incorporate a frequency for UFH to guide use. TID UFH is superior in efficacy to BID UFH even when taking into consideration the increased rate of major bleeds. Newly published risk-assessment models may be beneficial in determining which patients would best benefit from BID UFH or TID UFH.


Venous thromboembolism prevention Unfractionated heparin Low molecular weight heparin Efficacy Safety Case-fatality rates Risk-assessment models 


  1. 1.
    Edelsberg J, Hagiwara M, Taneja C et al (2006) Risk of venous thromboembolism among hospitalized medically ill patients. Am J Health-Syst Pharm 63(Suppl 6):S16–S22CrossRefPubMedGoogle Scholar
  2. 2.
    Spencer FA, Lessard D, Emery C et al (2007) Venous thromboembolism in the outpatient setting. Arch Intern Med 167:1471–1475CrossRefPubMedGoogle Scholar
  3. 3.
    Hull RD, Schellong SM, Tapson VF et al (2007) Late breaking clinical trial: extended-duration venous thromboembolism (VTE) prophylaxis in acutely ill medical patients with recent reduced mobility: the exclaim study, presented at the XX1st congress of the international society of thrombosis and hemostasis, Geneva, Switzerland. J Thromb Haemost 5(Suppl 2) Abstract number: O-S-001Google Scholar
  4. 4.
    Anderson FA, Spencer FA (2003) Risk factors for venous thromboembolism. Circulation 107:I-9–I-16CrossRefGoogle Scholar
  5. 5.
    Ageno W, Becattini C, Brighton T et al (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117:93–102CrossRefPubMedGoogle Scholar
  6. 6.
    Kahn S, Ginsberg JS (2004) Relationship between deep venous thrombosis and the postthrombotic syndrome. Arch Intern Med 164:17–26CrossRefPubMedGoogle Scholar
  7. 7.
    Pengo V, Lensing AW, Prins MH et al (2004) Thromboembolic pulmonary hypertension study group. N Engl J Med 350:2257–2264CrossRefPubMedGoogle Scholar
  8. 8.
    Linkins L, Choi PT, Douketis JD (2003) Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism. Ann Intern Med 139:893–900PubMedGoogle Scholar
  9. 9.
    Willey VJ et al (2004) Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 26:1149–1159CrossRefPubMedGoogle Scholar
  10. 10.
    Prandoni P, Lensing AW, Cogo A et al (1996) The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 125:1–7PubMedGoogle Scholar
  11. 11.
    Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism. Chest 133:381S–453SCrossRefPubMedGoogle Scholar
  12. 12.
    Nicolaides AN, Fareed J, Kakkar AK et al (2006) Int Union Ang 25:101–161 [International Consensus Statement]Google Scholar
  13. 13.
    Mandala M, Falanga A, Piccioli A et al (2006) Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM). Crit Rev Oncol Hematol 59:194–204CrossRefPubMedGoogle Scholar
  14. 14.
    Ageno W, Agnelli G, Checcia G, Cimminiello C, Paciaroni M, Palareti G, Pini M, Piovella F, Pogliani E, Testa S (2009) Prevention of venous thromboembolism in immobilized neurological patients: guidelines of the Italian society for hemostasis and thrombosis (SISET). Thromb Res 124:e26–e31 (Epub 2009 Jul 30)CrossRefPubMedGoogle Scholar
  15. 15.
    Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology Guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505Google Scholar
  16. 16.
    NCCN Practice Guidelines in Oncology, Venous Thromboembolic disease. Accessed 8 Nov 2009
  17. 17.
    Lacy CF, Armstrong LL, Goldman, MP et al (2008–2009) Drug information handbook, 17th edn. Lexi-Comp, Ohio, pp 749–752Google Scholar
  18. 18.
    Winter ME, Basic clinical pharmacokinetics, 4th edn. Lippincott Williams & Wilkins, Philadelphia, p 46. ISBN-10:0781741475, ISBN-13:978-0781741477Google Scholar
  19. 19.
    Tapson VF, Decousus H, Pini M et al (2007) IMPROVE investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest 132:936–945 (IMPROVE)CrossRefPubMedGoogle Scholar
  20. 20.
    Clagett GP, Reish RS (1988) Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 208:227–240CrossRefPubMedGoogle Scholar
  21. 21.
    King CS, Holley AB, Jackson JL et al (2007) Twice vs three times daily heparin dosing for thromboembolism prophylaxis in the general medical population. Chest 131:507–516CrossRefPubMedGoogle Scholar
  22. 22.
    Hirsh J, Bauer KA, Donati MB et al (2008) American College of Chest Physicians. Parenteral anticoagulants. Chest 133:141S–159SCrossRefPubMedGoogle Scholar
  23. 23.
    Yalamanchili K, Sukhija R, Sinha N et al (2005) Efficacy of unfractionated heparin for thromboembolism prophylaxis in medical patients. Am J of Therapeutics 12:293–299CrossRefGoogle Scholar
  24. 24.
    Wein L, Wein S, Haas SJ et al (2007) Pharmacological venous thromboembolism prophylaxis in hospitalized medical patients. Arch Intern Med 167:1476–1486CrossRefPubMedGoogle Scholar
  25. 25.
    Gardlund B, Hammers S, Arneborn P et al (1996) Randomised, controlled trial of low-dose heparin for prevention of fatal pulmonary embolism in patients with infectious diseases: the Heparin Prophylaxis Study Group. Lancet 347:1357–1361CrossRefPubMedGoogle Scholar
  26. 26.
    Spyropoulos AC (2005) Emerging strategies in the prevention of venous thromboembolism in hospitalized medical patients. Chest 128:958–969CrossRefPubMedGoogle Scholar
  27. 27.
    Hillbom M, Erila T, Sotaneiemi K et al (2002) Enoxaparin vs. heparin for prevention of DVT in acute ischaemic stroke: a randomized, double-blind study. Acta Neurol Scand 106:84–92CrossRefPubMedGoogle Scholar
  28. 28.
    Diener H, Ringelstein EB, von Kummer R et al (2006) Prophylaxis of thrombotic and embolic events in acute ischemic stroke with low-molecular-weight heparin certoparin, results of the PROTECT trial. Stroke 37:139–144CrossRefPubMedGoogle Scholar
  29. 29.
    Sherman DG, Albers GW et al (2007) The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison. Lancet 369:1347–1355CrossRefPubMedGoogle Scholar
  30. 30.
    Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1–12CrossRefPubMedGoogle Scholar
  31. 31.
    Bergmann JF, Neuhart E et al (1996) A multicenter randomized double-blind study of enoxaparin compared with unfractionated heparin in the prevention of venous thromboembolic disease in elderly in-patients bedridden for an acute medical illness. The Enoxaparin in Medicine Study Group. Thromb Haemost 76:529–534PubMedGoogle Scholar
  32. 32.
    Cade JF, Andrews JT, Stubbs AE (1982) Comparison of sodium and calcium heparin in prevention of venous thromboembolism. Aust N Z J Med 12:501–504PubMedGoogle Scholar
  33. 33.
    Samama MM, Cohen AT, Darmon JY et al (1999) A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. NEJM 341:793–800CrossRefPubMedGoogle Scholar
  34. 34.
    Lechler E, Schramm W, Flosbach CW et al (1996) The venous thrombotic risk in non-surgical patients: epidemiological data and efficacy/safety profile of a low-molecular-weight heparin (enoxaparin). The Prime Study Group. Prophylaxis in internal medicine with enoxaparin (PRIME). Haemostasis 26(Suppl 2):49–56Google Scholar
  35. 35.
    Kleber FX, Witt C, Vogel G et al (2003) THE-PRINCE Study Group (PRINCE) Prevention IN cardiopulmonary diseases with enoxaparin. Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease. Am Heart J 145:614–621CrossRefPubMedGoogle Scholar
  36. 36.
    Harenberg J, Kallenbach B, Martin U et al (1990) Randomized controlled study of heparin and low molecular weight heparin for prevention of deep-vein thrombosis in medical patients. Thromb Res 59:639–650CrossRefPubMedGoogle Scholar
  37. 37.
    Harenberg J, Roebruck P, Heene DL et al (1996) Subcutaneous low-molecular weight heparin versus standard heparin and the prevention of thromboembolism in medical inpatients. Haemostasis 26:127–139PubMedGoogle Scholar
  38. 38.
    Mismetti P, Laporte-Simitsidis S, Tardy B et al (2000) Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 83:14–19PubMedGoogle Scholar
  39. 39.
    Alikhan R, Cohen AT (2009) Heparin for the prevention of venous thromboembolism in general medical patients (excluding stroke and myocardial infarction). The Cochrane Library, art no. CD003747, pp 1–26Google Scholar
  40. 40.
    Naess IA, Christiansen SC, Romundstad P et al (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5:692–699CrossRefPubMedGoogle Scholar
  41. 41.
    Stein PD, Kayali F, Olsoon RE et al (2004) Estimated case fatality rate of pulmonary embolism, 1979 to 1998. Am J Cardiol 93:1197–1199CrossRefPubMedGoogle Scholar
  42. 42.
    Anderson FA, Wheeler HB, Goldberg RJ et al (1991) A population-based perspective of the hospital incidence and case fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Intern Med 151:933–938CrossRefPubMedGoogle Scholar
  43. 43.
    Heit JA, Silverstein MD, Mohr DN et al (1999) Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med 159:445–453CrossRefPubMedGoogle Scholar
  44. 44.
    Douketis JD et al (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462CrossRefPubMedGoogle Scholar
  45. 45.
    Cohen AT, Davidson BL, Gallus AS et al (2006) ARTEMIS investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ 332:325–329CrossRefPubMedGoogle Scholar
  46. 46.
    Leizorovicz A, Cohen AT, Turpie AG et al (2004) PREVENT medical thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 110:874–879CrossRefPubMedGoogle Scholar
  47. 47.
    Piazza G, Seddighzadeh A, Goldhaber SZ (2007) Double trouble for 2,609 hospitalized medical patients who developed deep vein thrombosis: prophylaxis omitted more often and pulmonary embolism more frequent. Chest 132:554–561CrossRefPubMedGoogle Scholar
  48. 48.
    Salzman EW, Hirsh J (1994) Prevention of venous thromboembolism. In: Colman RW, Hirsh J, Marder VJ et al (eds) Hemostasis and thrombosis: basic principles and clinical practice, 3rd edn. JB Lippincott, Philadelphia, PA, p 1332Google Scholar
  49. 49.
    Wheeler AP (2005) Identifying at-risk patients for venous thromboembolism prophylaxis. In: Merli GJ (ed) Thrombosis: prophylaxis of venous thromboembolism. Elsevier, Bridgewater, pp 9–21Google Scholar
  50. 50.
    Lutz L, Haas S, Hach-Wunderle V et al (2002) Venous thromboembolism in internal medicine; risk assessment and pharmaceutical prophylaxis. Med Welt 53:231–234Google Scholar
  51. 51.
    Kucher N, Koo S, Quiroz R et al (2005) Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med 352:969–977CrossRefPubMedGoogle Scholar
  52. 52.
    Cohen AT, Alikhan R, Arcelus JI et al (2005) Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost 94:750–759PubMedGoogle Scholar
  53. 53.
    Spyropoulos AC, Anderson FA, Fitzgerald G et al (2009) Venous thromboembolism risk factors in acutely ill hospitalized medical patients: findings from the improve registry, Presented at the XXIInd congress of the international society of thrombosis and hemostasis, Boston, Massachusetts. J Thromb Haemos 7(Suppl 2) Abstract OC-MO-052Google Scholar
  54. 54.
    Imberti D, Prisco D (2005) Venous thromboembolism prophylaxis in medical patients: future perspectives. Thromb Res 116:365–375CrossRefPubMedGoogle Scholar

Copyright information

© SIMI 2010

Authors and Affiliations

  • Charles E. Mahan
    • 1
  • Mario Pini
    • 2
  • Alex C. Spyropoulos
    • 3
  1. 1.Cardinal Health Pharmacy Solutions, Lovelace Medical Center, Lovelace Rehabilitation Hospital, Lovelace Health SystemsAlbuquerqueUSA
  2. 2.Medicina Interna IIOspedale di FidenzaParmaItaly
  3. 3.Thrombosis Unit, Hamilton General HospitalMcMaster UniversityHamiltonCanada

Personalised recommendations